The round was led by Debiopharm Innovation Fund in conjunction with Tesi, a Finnish venture capital and private equity company, and was supported by BC Platforms’ existing investors.
To date, the company has established partnerships with over 50 enterprise level healthcare units and biobanks globally in 19 countries representing more than 2 million subjects.
“We are delighted to have been supported by Debiopharm Innovation Fund and Tesi in this new financing round. This funding will enable us to progress to our next stage of expansion and to launch our new knowledge based solutions for R&D customers worldwide. Debiopharm’s experience in drug development will provide us with invaluable insight as we launch this major new initiative,” says Tero Silvola, CEO at BC Platforms.
“We see big data as a core asset in research and development. We are excited to have invested in BC Platforms and look forward to working with them to unlock the potential of big data to dramatically improve R&D productivity and provide clinical benefits to patients. BC Platforms fits directly with our fund’s vision to invest in innovative companies that change the way we develop drugs and treat patients,” says Tanja Dowe, Head of Debiopharm Innovation Fund.
